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Background: The clinical course of gastric lymphoma is heterogeneous and clinical symp-
toms and some factors have been related to prognosis.
Objective: The present study aims to identify prognostic factors in gastric diffuse B-cell non-
Hodgkin lymphoma diagnosed and treated in different countries.
Methods: A consecutive series of gastric diffuse B-cell non-Hodgkin lymphoma patients diag-
nosed  and treated in Brazil, Portugal and Italy, between February 2008 and December 2014
was  evaluated.
Results: Of 104 patients, 57 were female and the median age was 69 years (range: 28–88). The
distribution of the age-adjusted international prognostic index was 12/95 (13%) high risk,
20/95 (21%) high-intermediate risk and 63/95 (66%) low/low-intermediate risk. Symptoms
included abdominal pain (63/74), weight loss (57/73), dysphagia (37/72) and nausea/vomiting
(37/72). Bulky disease was found in 24% of the cases, anemia in 33 of 76 patients and bleeding
in  22 of 72 patients. The median follow-up time was 25 months (range: 1–77 months), with
1-  and 5-year survival rates of 79% and 76%, respectively. The multivariate Cox Regression
identiﬁed the age-adjusted international prognostic index as a predictor of death (hazard
risk:  3.62; 95% conﬁdence interval: 2.21–5.93; p-value <0.0001).
Conclusions: This series identiﬁed the age-adjusted international prognostic index as pre-
dictive of mortality in patients treated with conventional immunochemotherapy.© 2016 Associac¸a˜o Bra
by  Elsevier Editora Lt
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Introduction
Gastric lymphoma is the most common extra nodal diffuse
B-cell non-Hodgkin lymphoma (DLBCL) and accounts for 30%
of cases of lymphoma in the stomach.1 According to the cur-
rent WHO  lymphoma classiﬁcation criteria, gastric DLBCLs
are classiﬁed with or without features of MALT.2 Recent stud-
ies revealed that Helicobacter pylori-related gastric DLBCL is a
distinct less aggressive entity with greater chemosensitivity,
thereby highlighting the heterogeneity of these lymphomas.
The clinical presentation and course are also variable with
clinical symptoms, laboratorial abnormalities and H. pylori,
hepatitis B, and C infections, in addition to classical inter-
national prognostic index (IPI) factors having been related to
prognosis.3 Different clinical behaviors may reﬂect distinct
unidentiﬁed pathogenic mechanisms.4 A better characteri-
zation of prognostic factors is required in order to discover
new potential disease mechanisms, improve outcomes and
individualize treatment approaches. The present study aims
to identify prognostic factors in patients with gastric DLBCL
diagnosed and treated in different countries by analyzing
demographic and clinical characteristics, response to treat-
ment and outcome.
Patients
A retrospective study of 104 consecutive patients with DLBCL
diagnosed and treated in hematology centers in Brazil, Italy
and Portugal between February 2008 and December 2014 was
performed. The inclusion criteria were age >18 years old,
lymphoma primarily located in the stomach, with or with-
out the involvement of other intra-abdominal structures and
with a conﬁrmed DLBCL histology. All cases were diagnosed
according to World Health Organization (WHO) classiﬁcation
criteria.2 Patients with transformation from another type of
lymphoma to DLBCL were excluded. Patients were considered
H. pylori positive when their histology results were positive.
Data were retrieved from patient’s charts with all patients
having signed a consent form submitted to the local ethics
committee in the diagnosis period. All patients were subjected
to a detailed physical evaluation including an investigation
of B symptoms (pain, nausea, dysphagia, bleeding, obstruc-
tion), routine blood exams (hemoglobin, total and differential
leukocyte counts, platelet count and peripheral smear for
abnormal/blast cells), biochemical exams [liver function
tests, serum lactate dehydrogenase (LDH), 2 microglobulin,
albumin, urea, creatinine and uric acid] and serologic investi-
gations for hepatitis B and C and HIV. Upper gastrointestinal
endoscopic examinations were performed in 95% of the
patients. Imaging studies included chest radiographs and/or
computed tomography scans and abdominal and pelvic com-
puted tomography scans or ultrasonography. Bulky disease
was deﬁned as lesions with a diameter >10 cm. All patients
underwent bone marrow aspiration and biopsy as part of the
staging procedure. The international prognostic index (IPI),
age-adjusted IPI (aaIPI)5 and Ann Arbor stage6,7 were calcu-
lated for each patient.
All patients were treated by systemic chemotherapy mostly
consisting of six cycles of the rituximab, cyclophosphamide, 2 0 1 6;3  8(3):247–251
doxorubicin, vincristine and prednisone (R-CHOP) regimen
with the intention to cure.8 Patients with residual disease
received local radiotherapy. Imaging studies and endoscopic
examinations were used to evaluate response.
The inﬂuence of the following parameters were evaluated
in the response to treatment and survival: LDH, 2 microglob-
ulin, albumin, presence of bulky disease, B symptoms (fever,
weight loss, pain, nausea, vomiting), aaIPI, type of treatment
(surgery plus chemotherapy, chemotherapy alone), anemia,
dysphagia, bleeding, obstruction and presence of H. Pylori at
diagnosis. Anemia was deﬁned as hemoglobin <12.0 g/dL and
elevated LDH levels as >240 U/L.
All patients underwent imaging and follow-up endoscopic
examinations (with a biopsy of suspicious lesions) to doc-
ument treatment response. At the end of chemotherapy,
response was classiﬁed as complete remission (CR), par-
tial response (PR), stable disease (SD) or progressive disease
(PD) according to the International Working Group criteria.6
Patients who failed initial therapy with R-CHOP (PR, SD and
PD) received high-dose chemotherapy together with autolo-
gous stem cell transplant. Patients with H. pylori at diagnosis
also received antibiotic therapy.
Statistical  analysis
Survival was estimated using the Kaplan–Meier method and
compared using the log-rank test. The prognostic value of
the different variables for clinical outcome was estimated by
univariate and multivariate analyses, applying the Cox propor-
tional hazards regression model. Two-sided p-value <0.05 was
considered signiﬁcant. The Statistical Package for the Social
Sciences (SPSS version 15.0) software (Chicago, IL, USA) was
used for data analysis.
Results
Clinical  and  histological  features
The clinic pathologic characteristics of the 47 male (45%) and
57 female (55%) patients with gastric DLBCL with a median
age of 69 years (range: 28–88 years) are listed in Table 1. The
main presenting symptom was abdominal pain (85% of the
cases) and the two most common serum alterations were
elevations in 2 microglobulin and LDH in 71% and 41% of
the cases, respectively. Hypoalbuminemia was found in 26/83
(31%) patients. Bleeding and obstruction were uncommon at
presentation and anemia was only present in 43% (33/76) of
cases. Among the 45 patients who were tested for H. pylori,
13 were positive. Localized disease (Ann Arbor stages I or II)
was present in 46% of the cases, and most patients (67%) were
in the low/low intermediate risk group according to the aaIPI;
48% had good performance status [Eastern Cooperative Oncol-
ogy Group (ECOG) score 0].Treatment,  outcome  and  prognostic  factors
Only 10% of the patients required surgery due to obstruction,
perforation or upper gastrointestinal bleeding. In contrast,
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Table 1 – Characteristics of patients at diagnosis.
Variable 104 cases
Gender (male) – n (%) 47 (45.2)
Age at diagnosis (median, range) 69 (28–88)
Presenting symptoms – n/total (%)
Abdominal pain 63/74 (85)
Weight loss 57/73 (78)
Nausea/vomiting 37/72 (51)
Bleeding 22/72 (30.5)
Anemia – n/total (%) 33/76 (43)
Dysphagia – n/total (%) 37/72 (51)
Helicobacter pylori infection – n/total (%) 13/45 (29)
Hepatitis B (Anti-HBc/HBsAg + )a – n/total (%) 45/97  (46.4)
Stage – n/total (%)
I–II 48/100 (46)
III–IV 52/100 (54)
ECOG – n/total (%)
0 49/101 (48.5)
1–2 43/101 (42.6)
≥3 09/101 (8.9)
Bulky disease (yes) – n/total (%) 25 (24)
B symptoms – n/total (%) 45/102 (44.1)
aaIPI – n/total (%)
0–1 64/95 (67.3)
2–3 31/95 (32.7)
Hypoalbuminemia – n/total (%) 26/83 (31)
Elevated ˇ2 microglobulin – n/total (%) 57/80 (71.2)
Elevated LDH – n/total (%) 41/99 (41.4)
Type of treatment: R-CHOP – n/total (%) 87/100 (87)
Alive – n/total (%) 82/104 (78.8)
Median follow-up n/range (months) censored group 25 (1–77)
ECOG: Eastern Cooperative Oncology Group score; aaIPI: age-
adjusted international prognostic index; LDH: lactate dehy-
drogenase; R-CHOP: Rituximab, cyclophosphamide, doxorubicin,
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Table 2 – Five-year survival rate according to clinical
features at diagnosis.
Variable No. of cases Five-year follow-up
n Survival rate p-Valuea
Ann Arbor stage
I-II 48 44 91 0.003
III-IV 52 35 64
Age-adjusted IPI
0–1 63 58 91 <0.0001
2–3 32 16 44
LDH levels
Normal 58 54 92 <0.0001
Abnormal 41 24 50
Anemia (Hb <12 g/dL)
No 43 36 83 0.007
Yes 33 19 54
B symptoms
No 57 53 91 <0.0001
Yes 45 27 56
Nausea/vomiting
No 35 29 82 0.04
Yes 37 23 60
Bulky disease
No 79 66 82 0.02
Yes 25 16 57
IPI: international prognostic index; LDH: lactate dehydrogenase.vincristine and prednisone.
a 5 patients with active disease.
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Figure 1 – The 5-year overall survival.a Log-rank test.
1–77 months), the 1- and 5-year survival rates were 79% and
76%, respectively. There were 22 deaths. Only four stage I–II
cases (18%) had progressive disease compared to 18 (82%)
patients with advanced disease hence, patients with local-
ized lymphoma (I–II) had a signiﬁcantly higher 5-year survival
probability (91%) compared with those with advanced-stage
(64%; p-value = 0.003). The 5-year survival of high-risk aaIPI
patients was signiﬁcantly inferior to low-risk patients (91%
versus 44%; p-value <0.0001: Table 2).
In the univariate analysis using Cox regression, several
variables were associated to the hazard risk (HR) for death
(Table 3). However, in the multivariate analysis just the aaIPI
Table 3 – Univariate analysis of hazard risk for death.
Variable HR 95% CI p-Value
Bulky disease 2.34 0.99–5.54 0.05
Hypoalbumenia 3.08 1.27–7.47 0.01
Stage III–IV 4.67 1.57–13.9 0.006
BM involvement 4.07 1.55–10.7 0.004
B symptoms 6.21 2.09–18.4 0.001
LDH abnormal 8.89 2.95–26.8 <0.0001
aaIPI 3.62 2.21–5.93 <0.0001
HR: hazard risk; 95% CI: 95% conﬁdence interval; BM: bone marrow;
LDH: lactate dehydrogenase; aaIPI: age-adjusted international pro-
gnostic index.
Signiﬁcance deﬁned as p-values <0.05.
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remained as predictive of mortality (HR: 3.62; 95% CI: 2.21–5.93;
p-value <0.0001).
Discussion
An unexpected high incidence of primary gastric DLBCL was
found in this multicenter series of patients treated at ter-
tiary care centers. Advanced stage was present in half of
the patients and one third had high-risk aaIPI. Regardless of
the prevalence of factors considered to be associated with
poor prognosis (advanced stage, B symptoms, bulky disease,
elevated LDH and high-risk aaIPI), the outcomes compared
favorably with registry data.9
The majority of the published data showed that pri-
mary  gastric DLBCL predominates in men.10,11 Interestingly,
in this cohort of Brazilian and European patients, a slightly
higher incidence was observed in women. Most patients had
advanced stage disease and a high-risk aaIPI at diagnosis. The
median age was 69 years old, ranging between 28 and 88 years,
which is in agreement with others studies.12,13 In nodal DLBCL,
an age higher than 60 years is a conﬁrmed poor prognostic
factor. Similar to another study, no relationship was found
between age and survival.14
The main clinical presentations of the disease were
non-speciﬁc gastrointestinal symptoms, including abdomi-
nal pain, nausea, vomiting and weight loss. Some authors
identiﬁed abdominal pain, gastrointestinal bleeding and
nausea/vomiting as the most common symptoms in large
cohorts of patients.12,15 The results of this study were sim-
ilar with 85% of evaluable patients developing abdominal
pain, 75% had weight loss and 51% had nausea. Ane-
mia, detected in 43% of the evaluable patients, was also
common. In general, the clinical manifestations of gastric
lymphoma are non-speciﬁc which may result in a delayed
diagnosis.
Low albumin levels have been suggested as an important
predictor of survival in elderly lymphoma patients and par-
ticularly in gastric DLBCL.16 In this study, 31% of the patients
had hypoalbuminemia, nevertheless, this hypothesis was not
conﬁrmed in the multivariate analysis.
Thirteen of the 45 patients who were tested for H. pylori
were positive. This is not a high incidence, but H. pylori infec-
tion plays a role in DLBCL.17 Hence, these patients were also
treated for H. pylori infection.
Univariate analysis conﬁrmed published data regarding
the prognostic impact of the aaIPI, ECOG, elevated DHL,
advanced stage, B symptoms, anemia, bulky disease and albu-
min  levels.10,15 Nevertheless, multivariate analysis showed
that only aaIPI retained its signiﬁcance as an independent
predictor of outcome. Almost one quarter of the patients had
bulky disease at diagnosis and this turned out to be a negative
impact factor, and although rituximab decreased the adverse
prognostic value of bulky disease, it did not eliminate the
effect completely.18
One of the limitations of this study is its retrospective
design however this was the best way to get a relevant num-
ber of the patients with similar clinical features. The aaIPI was
identiﬁed as a predictor of survival in patients treated with
conventional immunochemotherapy.
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